

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Leishmaniasis	Not applicable	A mouse study suggests that adding sand fly-specific antigens to current vaccines against <i>Leishmania major</i> may be useful for increasing vaccine protection. Sand flies, which can carry the <i>L. major</i> parasite, have salivary proteins that promote neutrophil recruitment and inflammation. Mice treated with neutrophil-depleting antibodies prior to <i>L. major</i> exposure from sand flies had significantly fewer infections than controls ( $p=0.02$ at 1 week; $p=0.002$ at 4 weeks). Intravital microscopy and flow cytometry studies showed that <i>L. major</i> parasites phagocytosed by neutrophils remained viable and initiated infection. Next steps include determining how neutrophils at <i>L. major</i> infection sites affect vaccine efficacy.	Use of sand fly salivary proteins in a leishmaniasis vaccine is patented; available for licensing through the National Institute of Allergy and Infectious Diseases	Peters, N.C. <i>et al.</i> <i>Science</i> ; published online Aug. 14, 2008; doi:10.1126/science.1159194 <b>Contact:</b> David Sacks, National Institute of Allergy and Infectious Diseases, Bethesda, Md. e-mail: <a href="mailto:dsacks@nih.gov">dsacks@nih.gov</a> <b>Contact:</b> Jackson G. Egen, same affiliation as above e-mail: <a href="mailto:jegen@niaid.nih.gov">jegen@niaid.nih.gov</a>